Teamshares TMS
$3.91 −$0.24 (-5.78%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.91 0.00%
Open$4.03
Prev close$4.15
Day range$3.88 – $4.31
Volume82.8K
Market cap$283.47M
P/E (TTM)–
Dividend yield–
TMS Stock News
Headlines matching Teamshares or the TMS ticker, most recent first.
- TMS: Our Chairman of the Board, Keiji Hasumi (Distinguished Professor at Tokyo University of Agriculture and Technology), will appear on NHK E-TV's program "The Villains' Side of the Story."
- EDAP TMS | 4: Statement of changes in beneficial ownership of securities-Officer Mobeck Kenneth S.
- EDAP TMS | 4: Statement of changes in beneficial ownership of securities-Director Horn David R.
- EDAP TMS S.A. Q2 2026 Earnings Preview
- Mizuho Securities Initiates EDAP TMS(FOCL.US) With Buy Rating, Announces Target Price $15
- Northland Securities Initiates Teamshares(TMS.US) With Buy Rating, Announces Target Price $14
- H.C. Wainwright Maintains EDAP TMS(EDAP.US) With Buy Rating, Maintains Target Price $10
- EDAP TMS: EDAP TMS S.A. - Symbol Change Option Symbol: EDAP New Symbol: FOCL
- EDAP TMS | 4: Statement of changes in beneficial ownership of securities-Officer Mobeck Kenneth S.
- H.C. Wainwright Maintains EDAP TMS(EDAP.US) With Buy Rating, Cuts Target Price to $10 Negative
- TMS Co., Ltd. Posts Continued Losses but Maintains Strong Equity Base in Shortened Fiscal Year Mixed
- Lucid Capital Maintains EDAP TMS(FOCL.US) With Buy Rating, Cuts Target Price to $8 Negative
- H.C. Wainwright Maintains EDAP TMS(FOCL.US) With Buy Rating, Maintains Target Price $10
- TMS: The research team of the GLORIA clinical trial for glioblastoma, which utilizes NOX-A12, has been awarded the "German University Medicine Prize" — recognizing its innovative therapeutic approach and outstanding clinical trial results.
- BrainsWay Expands U.S. Insurance Coverage for Deep TMS Treatment of OCD to Over 118 Million Lives Positive
No comments yet — be the first to weigh in on TMS.
Sign in to join the discussion.